HeartBeam Launches Mount Sinai AI Collaboration Using FDA-Cleared 3D ECG Platform
HeartBeam partnered with Mount Sinai to develop AI-ECG algorithms using its patented 3D ECG platform and combined real-world and clinically annotated datasets. The FDA cleared its 3D ECG technology for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis in December 2025.
1. Strategic AI Collaboration with Mount Sinai
HeartBeam has entered a collaboration with the Icahn School of Medicine at Mount Sinai to co-develop and validate next-generation AI-ECG algorithms. The partnership leverages HeartBeam’s patented 3D ECG platform—the only system capable of continuous synthesized 12-lead ECG capture at home—and combines real-world longitudinal and clinically annotated data.
2. Regulatory Milestones
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis in December 2025. These approvals provide a regulatory foundation for the expanded AI applications targeted by the collaboration, paving the way for new clinical indications and reimbursement pathways.
3. Commercial and Clinical Implications
By integrating synthesized 12-lead ECG data with AI analytics, the collaboration aims to accelerate personalized heart attack risk assessment and broader predictive cardiology. The resulting data engine could unlock new markets, deepen clinical validation, and support HeartBeam’s entry into home-based diagnostic and monitoring services.